Navigation Links
Volcano Reports Third Quarter Results

SAN DIEGO, Nov. 4, 2013 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the third quarter and first nine months of 2013.

The company also today announced a strategic reprioritization and reallocation of resources within its distribution, research and development and clinical programs to focus on areas of strong projected growth in FFR (Fractional Flow Reserve), peripheral applications, coronary IVUS (Intravascular Imaging) driven by the ADAPT-DES clinical data and Axsun Medical. This has resulted in a corporate restructuring charge that reflects the discontinuation of certain product development programs effective September 30, 2013.

For the quarter ended September 30, 2013, Volcano reported revenues of $95.8 million versus revenues of $93.7 million in the same period a year ago. On a constant currency basis, revenues increased eight percent year-over-year after adjusting for a negative impact of approximately $5.4 million from foreign currency. Medical segment revenues increased approximately three and nine percent on a reported and constant currency basis, respectively.

The company reported a net loss on a GAAP basis of $8.5 million, or $0.15 per share, in the third quarter of 2013, versus net income of $2.0 million, or $0.04 per diluted share, in the same period a year ago. The results for the third quarter of 2013 included non-cash restructuring charges for the impairment  of intangible assets of $4.6 million, acquisition-related expenses of $1.3 million and net interest expense of $6.4 million versus $1.6 million a year ago, reflecting the company's convertible debt offering completed in the fourth quarter of 2012. Excluding acquisition-related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported a non-GAAP loss of $0.08 per share.

For the first nine months of 2013, Volcano reported revenues of $290.4 million versus $279.4 million a year ago. This represents an increase of four percent on a reported basis versus the same period a year ago and nine percent on a constant currency basis after adjusting for a $15.1 million negative effect from foreign currency. Medical segment revenues increased five and ten percent on a reported and constant currency basis, respectively. The company reported a net loss on a GAAP basis of $14.0 million, or $0.26 per share, for the first nine months of 2013, versus net income on a GAAP basis of $5.5 million, or $0.10 per diluted share, in the same period a year ago. The results for the first nine months of 2013 include net interest expense of $18.9 million versus $4.3 million a year ago. In addition, the company recorded an expense of $3.7 million related to acquisitions and a gain of $4.1 million related to the sale of a strategic investment, as well as the restructuring charge recorded in the third quarter of 2013. The company also recorded an exchange rate loss of $1.0 million in the first nine months of 2013 versus $319,000 in the same period a year ago. Excluding acquisition-related items, amortization of intangibles and non-cash interest expenses on convertible notes, net of tax, the company reported a non-GAAP net loss per share of $0.03.

"Overall, our business experienced solid growth. Growth drivers included a  seven percent increase in our U.S. IVUS revenues, due in great part to a roughly 30 percent increase in peripheral revenues versus the third quarter a year ago, as well as a  27 percent increase in combined  revenues in Europe,"  said Scott Huennekens, president and chief executive officer.

"At the same time, our U.S. coronary IVUS revenues were impacted by the continued decline in PCI volumes, although we are beginning to see some stabilization in activity. Also, despite the growth in our FFR business in Japan, revenues were not to our expectations," he added.

"We are finishing 2013 with strong momentum in our market expansion and product development programs. In addition to our growth in the peripheral market and revenues from the sale of  the PioneerPlus™ Re-Entry catheter that we acquired during the quarter, we have initiated a limited market release for our Crux® inferior vena cava (IVC) filter and the full market release of our Verrata™ everyday pressure wire," Huennekens noted.

"Volcano also had a very strong showing at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference. Data from our ADAPT DES study demonstrated the use of IVUS in stent patients changed the procedure 74 percent of the time and was associated with reductions in serious patient events, including stent thrombosis and myocardial infarction, as well as target lesion revascularizations—particularly for patients with more complex lesions. Additionally, the full results from our ADVISE II study showed that a hybrid iFR® (Instant Wave-Free Ratio) approach correctly matched an FFR-only approach in more than 94 percent of coronary stenoses and successfully avoided usage of adenosine in 65 percent of patients, reflecting findings from earlier studies in the use of our iFR technology," he said.

The strategic reprioritization program announced today is designed to enhance the allocation of resources and improve operating predictability and results. Key elements of the initiative include the discontinuation of development programs for the company's Forward-Looking IVUS, Forward-Looking Intra-Cardiac Echo and Optical Coherence Tomography intravascular imaging products.  The operating expenses associated with these three discontinued programs were approximately $12.0 million annually.  In addition to the restructuring charge recorded in the third quarter of 2013, the company expects to record a restructuring charge of up to $15.0 million, including up to $7.0-$7.5 million in cash charges, in the fourth quarter of 2013.

"We will be reinvesting the savings from this reprioritization of resources in higher growth, lower risk revenue generating product and market development opportunities. These include peripheral, FFR and expanded distribution. We believe this reprioritization initiative better focuses and positions Volcano to compete more effectively in our growth markets," Huennekens said.

"The opportunities that will be contributing revenues in 2014 include the expanded distribution in the peripheral market and the commercialization of our new offerings, including our Crux IVC filter, the Sync-Rx platform technology, PioneerPlus and Verrata. In addition, we expect to drive further penetration of our iFR offering in Japan and Europe, and anticipate regulatory approval and commercial launch of iFR in the U.S. in the second half of 2014," Huennekens noted.


The company confirmed revenue guidance for 2013 provided on October 28, 2013. Based on current foreign currency exchange rates, it expects revenues on a reported basis of $391.0-$395.0 million, with revenues on a constant currency basis in the range of $411.0-$415.0 million. Medical segment revenues are expected to increase approximately nine-to-ten percent on a constant currency basis.

The company also provided updated guidance and now expects gross margins on a reported basis will be in the range of 64.0-65.0 percent and that operating expense, including restructuring charges, will be 71.0-72.0 percent of revenues. On a reported basis, the company expects a GAAP net loss of $0.56-$0.58 per share and a non-GAAP net loss of $0.25-$0.27 per share. Non-GAAP results exclude acquisition-related expenses, amortization of intangibles and non-cash interest expense, and assume an effective tax rate of 38.0 percent for the GAAP to non-GAAP adjustments. The impact of restructuring charges in 2013 will be up $0.21 per share on both a GAAP and non-GAAP basis. The company expects weighted average basic shares in 2013 will be approximately 54.6 million shares and approximately 56.2 million shares on a diluted basis.

The company confirmed preliminary revenue guidance for 2014 as provided on October 28, 2013. It expects revenues will increase year-over-year in the range of nine-to-11 percent on a reported basis and eight-to-ten percent on a constant currency basis. Its outlook for 2014 reflects several factors, including an expectation that PCI's will be down approximately 2.5 percent in the U.S., two percent in Japan and flat in Europe year-over-year, and the anticipation of a reimbursement reduction of approximately 7.5 percent for all of its disposable products in Japan, beginning in the second quarter of the year.

Conference Call Information

The company will hold a conference call at 2 p.m., Pacific Standard Time, (5 p.m., Eastern Standard Time) today. The teleconference can be accessed by calling (631) 291-4555, passcode 71109347, or via the company's website at Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through November 11, at (404) 537-3406, passcode 71109347, and via the company's website at

About Volcano

Volcano Corporation (Nasdaq: VOLC) is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using light and sound as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at

Note Regarding the Use of Non-GAAP Financial Measures

The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The company uses non-GAAP financial measures for financial and operational decision making and as a means to compare period-to-period results. The company believes that they provide useful information about operating results, enhance the overall understanding of operating results and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

Constant Currency Basis Revenue Changes: Volcano reports changes in revenues on a constant currency basis, which is a non-GAAP financial measure. Volcano believes that investors' understanding of the company's short-term and long-term financial results is enhanced by taking into consideration the impact of foreign currency translation on revenue. In addition, Volcano's management uses results of operations before currency translation to evaluate the operational performance of Volcano and as a basis for strategic planning.

Volcano reports its expectations of earnings per share performance for excluding certain expenses described below; for additional details please see the "Reconciliation of GAAP to non-GAAP EPS Guidance" table in this press release. This accompanying table has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.

Exclusion of Acquisition-Related Expenses: Volcano excludes acquisition-related expenses because it does not considerer these acquisition-related costs and adjustments to be related to the continuing organic operations of the acquired businesses and are generally not relevant to assessing or estimating the long-term performance of the acquired assets. In addition, the size, complexity and/or volume of past acquisitions, which often drive the magnitude of acquisition-related costs, may not be indicative of the size, complexity and/or volume of future acquisitions.

Exclusion of Amortization of Intangibles: Volcano excludes amortization of intangibles because it is a non-cash expense relating primarily to acquisitions. At the time of an acquisition, the intangible assets of the acquired company, which consist of technology and supplier agreements, are valued and amortized over their estimated lives. Volcano believes that since intangible assets represent efforts of the acquired company to build value prior to acquisition, Volcano management eliminates the impact of the amortization when evaluating its current operating performance.

Exclusion of Non-Cash Interest Expenses: In addition to disclosing the financial statement impact of the authoritative guidance for convertible debt accounting, Volcano management believes that excluding the impact of this authoritative guidance because it is non-cash in nature, may provide meaningful supplemental information regarding elements of the company's borrowing costs in order to properly understand its operational performance and liquidity, and facilitates comparisons to competitors' results.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding Volcano's expected revenues, revenue growth, margins, financial results and foreign currency exchange rates for the quarter and year ended December 31, 2013, and the calendar year 2014, the benefits of the resource reprioritization described above, its growth and other strategies and ability to execute on those strategies, competitive positioning, target markets, development of its base business and pipeline, benefits from recent acquisitions and benefits from its products and technologies. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risk that Volcano's revenue, expense, earnings, earnings per share, margin or other projections may turn out to be inaccurate or Volcano may encounter unanticipated difficulty in achieving these projections; global and regional macroeconomic conditions, generally, and in the medical device and telecom industries specifically; current exchange rate fluctuations; the effect of competitive factors and the company's reaction to those factors; purchasing decisions with respect to the company's products; the pace and extent of market adoption of the company's products and technologies; uncertainty in the process of obtaining regulatory approval or clearances for Volcano's products or devices; the success of Volcano's growth and other strategies, including the integration of recently-acquired businesses and our ability to integrate businesses from future acquisitions; risks associated with Volcano's international operations; timing and achievement of product development milestones; outcome of ongoing or future litigation; investigations and claims; the impact and benefits of market development and the related size of Volcano's addressable markets; our ability to protect our intellectual property; dependence upon third parties; unexpected new data, safety and technical issues; market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our 10-K for the year ended December 31, 2012, our 10-Q for the quarter ended June 30, 2013, and other filings made with the Securities and Exchange Commission, which should be read in conjunction with these financial results. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


  VOLCANO CORPORATION  CONDENSED CONSOLIDATED BALANCE SHEETS  (in thousands)  (unaudited)  September 30,  December 31, 20132012 Assets  Current assets: Cash and cash equivalents 

211,406$   330,635Short-term available-for-sale investments188,778140,960Accounts receivable, net 


66,96752,811Prepaid expenses and other current assets 

33,26021,773Total current assets 

576,708622,527 Long-term available-for-sale investments 

89,21044,385 Property and equipment, net 

119,965104,385 Intangible assets, net 

60,63150,657 Goodwill 

53,08251,577 Other non-current assets 

28,10428,813 Total Assets $
927,700$   902,344 Liabilities and Stockholders' Equity  Current liabilities: Accounts payable 

,284Accrued compensation 

23,61523,227Accrued expenses and other current liabilities 

24,47323,529Deferred revenues 

9,4539,789Contingent consideration 

2,9112,908Total current liabilities 

75,87075,737 Convertible senior notes 

396,211382,300 Other long-term debt 

1,2321,119 Deferred revenues 

4,4354,661 Contingent consideration, non-current portion 

29,65727,323 Other non-current liabilities 

7,0092,859Total liabilities 

514,414493,999 Stockholders' equity 

413,286408,345 Total Liabilities and Stockholders' Equity $
927,700$   902,344 

 VOLCANO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)Three Months Ended
September 30,Nine Months Ended
September 30,2013201220132012Revenues$




279,389Cost of revenues, excluding amortization of intangibles33,45833,248102,62494,797Gross profit62,35160,408187,760184,592Operating expenses:Selling, general and administrative45,47940,699134,784127,035Research and development16,60913,03250,21440,560Amortization of intangibles8347102,4882,470Acquisition-related items1,253-3,742-Restructuring charges4,616-4,874-Total operating expenses68,79154,441196,102170,065Operating (loss) income(6,440)5,967(8,342)14,527Interest income327223970656Interest expense(6,756)(1,844)(19,908)(4,993)Exchange rate gain (loss)54(218)(1,025)(319)Other, net(33)(23)4,144(31)(Loss) income before income tax(12,848)4,105(24,161)9,840Income tax (benefit) expense(4,392)2,130(10,156)4,295Net (loss) income$




5,545Net (loss) income per share:Basic$








0.10Shares used in calculating net (loss) income per share:Basic54,65253,65954,46653,309Diluted54,65255,26554,46655,097 

September 30,20132012Operating activitiesNet (loss) income



5,545Adjustments to reconcile net (loss) income to net cash provided by operating activities:Depreciation and amortization18,67717,448Amortization of investment premium, net 2,3052,023Accretion of debt discount on convertible senior notes14,1483,700Accretion of contingent consideration2,537-Non-cash stock-based compensation expense12,09811,428Asset impairment related to restructuring4,616-Other non-cash adjustments8,8722,502Changes in operating assets and liabilities(37,979)(5,362)Net cash provided by operating activities11,26937,284Investing activitiesPurchase of short-term and long-term available-for-sale investments(342,715)(237,669)Sale or maturity of short-term and long-term available-for-sale investments247,790188,556Capital expenditures(26,533)(36,589)Cash paid for acquisitions(15,000)-Cash paid for intangible assets and other investments(2,377)(3,107)Proceeds from sale of long-term investments3,426-Proceeds from foreign currency exchange contracts-1,187Payment for foreign currency exchange contracts-(215)Net cash used in investing activities(135,409)(87,837)Financing activitiesRepayment of debt(22)(68)Proceeds from sale of common stock under employee stock purchase plan3,5763,880Proceeds from exercise of common stock options2,2038,408Net cash provided by financing activities5,75712,220Effect of exchange rate changes on cash and cash equivalents(846)24Net decrease in cash and cash equivalents(119,229)(38,309)Cash and cash equivalents, beginning of period330,635107,016Cash and cash equivalents, end of period




 VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Three Months Ended
September 30,Percentage Change
2012 to 2013Currency Impact Constant Currency Percentage Change20132012DollarPercentageMedical segment:Consoles:United States

$   6.3$   6.05




0.60.8(19)$ (0.1)(20)1Europe

2.51.4780.1969Rest of world

1.61.52--2Total Consoles

$ 11.0$   9.713$   0.0(1)14IVUS single-procedure disposables:United States

$ 20.4$ 19.17





5.34.7120.366Rest of world

1.61.7(1)--(1)Total IVUS single-procedure disposables

$ 46.0$ 48.6(5)$ (4.3)(9)4FFR single-procedure disposables:United States

$ 14.3$ 13.010





8.36.5270.4621Rest of world

1.01.1(8)--(8)Total FFR single-procedure disposables

$ 27.9$ 24.613$ (0.7)(3)16Other

$   8.8$   7.813

%$ (0.4)(4)


%Sub-total medical segment

$ 93.7$ 90.73$ (5.4)(6)9Industrial segment

$   2.1$   3.0(28)$


$ 95.8$ 93.72$ (5.4)(6)8 

 VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Nine Months Ended
September 30,Percentage Change
2012 to 2013Currency Impact Constant Currency Percentage Change20132012DollarPercentageMedical segment:Consoles:United States

$   18.0$   17.81





6.74.2590.2554Rest of world

5.14.415--15Total Consoles

$   31.5$   28.510$   (0.2)(1)11IVUS single-procedure disposables:United States

$   60.4$   59.32





17.515.6120.4210Rest of world

6.05.119--19Total IVUS single-procedure disposables

$ 143.9$ 153.7(6)$ (11.8)(7)1FFR single-procedure disposables:-United States

$   43.0$   37.415





24.119.1270.5324Rest of world

3.02.331--31Total FFR single-procedure disposables

$   83.3$   67.723$   (2.2)(3)26Other

$   25.7$   21.321

%$   (0.9)(4)


%Sub-total medical segment

$ 284.4$ 271.25$ (15.1)(5)10Industrial segment



$ 290.4$ 279.44$ (15.1)(5)9 

 VOLCANO CORPORATIONRECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS(in thousands, except per share data)(Unaudited)Three Months Ended September 30, 2013Pre-tax AdjustmentsNet of Tax (1)Earnings Per Share GAAP net loss$
(0.15)Acquisition related items 

1,2537770.01Amortization of intangibles 

8345170.01Non-cash interest expense on convertible notes 

4,7602,9510.05 Non-GAAP net loss 

(0.08) Weighted average shares outstanding—diluted 54,652Nine Months Ended September 30, 2013Pre-tax AdjustmentsNet of Tax (1)Earnings Per Share GAAP net loss $
(0.26)Acquisition related items 

3,7422,3200.04Amortization of intangibles 

2,4881,5430.03Non-cash interest expense on convertible notes 

14,0288,6970.16Non-GAAP net loss 

(0.03) Weighted average shares outstanding—diluted 54,466(1) Effective tax rate of 38% applied to non-GAAP adjustments 

 VOLCANO CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP EPS GUIDANCE(in thousands, except per share data)(Unaudited)2013Guidance RangeFromTo GAAP net loss per share 

$  (0.58)$  (0.56)Acquisition related items 

.06Amortization of intangibles 

.04Non-cash interest expense 

.21 Non-GAAP net loss per share—basic and diluted 

$  (0.27)$  (0.25) Weighted average shares outstanding 

54,60054,600Note: Effective tax rate of 38% applied to non-GAAP adjustments 

SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):